Bioconjugate chemistryJan 16, 2026

Using stabilized micelles targeting glucose transporters to deliver mRNA noninvasively across the blood-brain barrier

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 28, 2026

Abstract

Essence

A glucose-targeted, disulfide-stabilized micelle used metabolic GLUT1 priming to deliver mRNA across the blood-brain barrier without invasive disruption.

Evidence

Evidence comes from a preclinical nanodelivery study using fasting-induced GLUT1 upregulation, intravital imaging, and brain GFP readouts, reporting 160-fold higher cerebral mRNA accumulation than untargeted controls and pan-brain expression within 120 minutes.

Caveat

The finding is based on an experimentally staged fasting-plus-glycemic-spike strategy in a preclinical system, so feasibility and generalizability for human CNS treatment are uncertain.

Simplified

The blood-brain barrier (BBB) remains the single most obstructive bottleneck to mRNA therapeutics for central nervous system (CNS) disorders. Here we introduce a metabolically primed, redox-locked nanoplatform that converts the brain's glucose addiction into a gate-cracking key. A disulfide-stabilized, glucose-decorated block-cationic copolymer self-assembles with mRNA into 36 nm micelles (ζ potential approximately +4.5 mV) that withstand serum nucleases and polyanionic assault yet disassemble on cytosolic glutathione. Fasting-induced GLUT1 upregulation (4.2-fold) is exploited as a transiently overexpressed "receptor"; a subsequent glycemic spike drives receptor-mediated transcytosis, yielding 160-fold higher cerebral mRNA accumulation versus untargeted controls. Single-cell intravital imaging confirms parenchymal penetration within 120 min and pan-brain GFP expression. The strategy affords spatiotemporally sharp CNS transfection without BBB disruption or systemic toxicity, offering a generalizable, nonviral avenue for genomic medicine of neurological diseases.